Next Article in Journal
Non-Invasive Delivery of Nano-Emulsified Sesame Oil-Extract of Turmeric Attenuates Lung Inflammation
Next Article in Special Issue
Focused Ultrasound and Microbubbles-Mediated Drug Delivery to Brain Tumor
Previous Article in Journal
Development and Characterization of Biointeractive Gelatin Wound Dressing Based on Extract of Punica granatum Linn
Previous Article in Special Issue
Pharmacokinetic Principles and Their Application to Central Nervous System Tumors
Review

Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors

1
Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, USA
2
Department of Biomedical Sciences, University of Minnesota Medical School—Duluth, Duluth, MN 55812, USA
3
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55902, USA
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2020, 12(12), 1205; https://doi.org/10.3390/pharmaceutics12121205
Received: 20 November 2020 / Revised: 8 December 2020 / Accepted: 10 December 2020 / Published: 11 December 2020
(This article belongs to the Special Issue Drug Delivery to Brain Tumors)
Effective treatments for brain tumors remain one of the most urgent and unmet needs in modern oncology. This is due not only to the presence of the neurovascular unit/blood–brain barrier (NVU/BBB) but also to the heterogeneity of barrier alteration in the case of brain tumors, which results in what is referred to as the blood–tumor barrier (BTB). Herein, we discuss this heterogeneity, how it contributes to the failure of novel pharmaceutical treatment strategies, and why a “whole brain” approach to the treatment of brain tumors might be beneficial. We discuss various methods by which these obstacles might be overcome and assess how these strategies are progressing in the clinic. We believe that by approaching brain tumor treatment from this perspective, a new paradigm for drug delivery to brain tumors might be established. View Full-Text
Keywords: blood-brain barrier; BTB; NVU/BBB; brain metastases blood-brain barrier; BTB; NVU/BBB; brain metastases
Show Figures

Graphical abstract

MDPI and ACS Style

Griffith, J.I.; Rathi, S.; Zhang, W.; Zhang, W.; Drewes, L.R.; Sarkaria, J.N.; Elmquist, W.F. Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors. Pharmaceutics 2020, 12, 1205. https://doi.org/10.3390/pharmaceutics12121205

AMA Style

Griffith JI, Rathi S, Zhang W, Zhang W, Drewes LR, Sarkaria JN, Elmquist WF. Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors. Pharmaceutics. 2020; 12(12):1205. https://doi.org/10.3390/pharmaceutics12121205

Chicago/Turabian Style

Griffith, Jessica I., Sneha Rathi, Wenqiu Zhang, Wenjuan Zhang, Lester R. Drewes, Jann N. Sarkaria, and William F. Elmquist 2020. "Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors" Pharmaceutics 12, no. 12: 1205. https://doi.org/10.3390/pharmaceutics12121205

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop